Showing results (401-410 of 542) with videos related to
Sort By:
Pageof 55
The British Journal of Surgery|February 18, 2022
Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinomaArnaldo N S Silva, Yuichi Saito, Takaki Yoshikawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.Journal of the National Cancer Institute|August 21, 2014
Risk of premature menopause after treatment for Hodgkin's lymphomaAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.Structure (London, England : 1993)|September 10, 2003
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenaseThomas A Pauly, Jennifer L Ekstrom, David A Beebe, et al.Acta Oncologica (Stockholm, Sweden)|February 15, 2021
Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection marginsRebecca K Bott, Kerri Beckmann, Janine Zylstra, et al.British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.British Journal of Cancer|April 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trialAnderley Gordon, Amina Tran, Caroline Fong, et al.Trials|August 31, 2017
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trialNick J Battersby, Mit Dattani, Sheela Rao, et al.British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.Pageof 55